Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiyen Biotech CoTPE:1737 83 EV-to-EBIT is 9.16 as of Aug. 29, 2026, which is 11% below its 10-year median of 10.32. GuruFocus rates TPE:1737 with a GF Score™ of 83/100 and a GF Value™ of NT$31.16 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,565 Consumer Packaged Goods companies, Taiyen Biotech Co ranks better than 65.94% on this metric.
Taiyen Biotech Co (TPE:1737) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Taiyen Biotech Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$4,643 Mil.
Taiyen Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$483 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiyen Biotech Co EV-to-EBIT Related Terms
Taiyen Biotech Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Taiyen Biotech Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Taiyen Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiyen Biotech Co EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Taiyen Biotech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Taiyen Biotech Co's EV-to-EBIT falls into.
Taiyen Biotech Co's current Enterprise Value is NT$4,423 Mil.
Taiyen Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$483 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiyen Biotech Co (TPE:1737) has a EV-to-EBIT of 9.16 as of Aug. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Taiyen Biotech Co and its competitors. This is 11% below median its historical median of 10.32. Over the past decade, Taiyen Biotech Co's EV-to-EBIT has ranged from 6.49 to 17.25. According to the industry distribution chart, Taiyen Biotech Co ranks #533 out of 1565 companies in the Consumer Packaged Goods industry, placing it in the top 34.1%.
Is Taiyen Biotech Co's EV-to-EBIT too high?
Taiyen Biotech Co's current EV-to-EBIT of 9.16 is 11% below median its 10-year median of 10.32. Over the past 10 years, this metric has ranged from a low of 6.49 to a high of 17.25. The Consumer Packaged Goods industry median EV-to-EBIT is 12.33. Taiyen Biotech Co's value of 9.16 is 25.7% below this industry median. Based on the distribution chart, Taiyen Biotech Co ranks #533 out of 1565 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Taiyen Biotech Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's EV-to-EBIT compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Taiyen Biotech Co ranks #533 out of 1565 companies for EV-to-EBIT. This puts Taiyen Biotech Co in the upper half of its industry. The industry median EV-to-EBIT is 12.33. Taiyen Biotech Co's value of 9.16 is 25.7% below this benchmark. Historically, Taiyen Biotech Co's own EV-to-EBIT has ranged from 6.49 to 17.25 over the past decade. While the company's 10-year median is 10.32 vs. the industry median of 12.33, Taiyen Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Consumer Packaged Goods company?
The median EV-to-EBIT among Consumer Packaged Goods companies is 12.33, based on 1,565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiyen Biotech Co's current EV-to-EBIT of 9.16 is 25.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Taiyen Biotech Co and its competitors. For the Consumer Packaged Goods industry, the median EV-to-EBIT is 12.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiyen Biotech Co's current EV-to-EBIT is 9.16, which is 11% below median its own 10-year median of 10.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.16, compared to a current price of NT$30.80 — trading 1.2% below its estimated fair value. The current EV-to-EBIT is 9.16, which is 11% below median its 10-year median of 10.32 and 25.7% below the Consumer Packaged Goods industry median of 12.33. Taiyen Biotech Co's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current EV-to-EBIT is 9.16 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?
Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be undervalued.
The current stock price of NT$30.80 is trading 1.2% below its estimated GF Value™ of NT$31.16.
GuruFocus considers Taiyen Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1737:
EV-to-EBIT: 9.16 (11% below median its 10-year median of 10.32)
GF Value™: NT$31.16 vs. price of NT$30.80 (1.2% below fair value)
Industry Position: 25.7% below the Consumer Packaged Goods median (#533 of 1565)
No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
83GF Score
Get the complete analysis for TPE:1737
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1737 has been successfully added to your 
